Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
Author:
Funder
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Publisher
Elsevier BV
Subject
Pharmacology
Reference38 articles.
1. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta;Apperley;N. Engl. J. Med.,2002
2. BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria
3. Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells;Brendel;Leukemia,2007
4. Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis;Calderón-Cabrera;Leuk. Res. Rep.,2013
5. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl;Carlesso;J. Exp. Med.,1996
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. JAK/STAT signaling pathway inhibitors for leukemia therapeutic potential : a systematic review on in vitro literatures;2024-09-02
2. JAK/STAT as therapeutic signaling pathway in leukemia: a systematic review on in vitro inhibitors;2024-08-06
3. Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia;Cancers;2022-07-06
4. The role of chlorine atom on the binding between acrylonitrile derivatives and fat mass and obesity‐associated protein;Journal of Molecular Recognition;2020-11-09
5. Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors;Current Opinion in Pharmacology;2020-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3